November 8th, 2023 4:30 PM Eastern Time r m a 1 > Lantern P h a r m a | --- | --- | --- | --- | --- | --- | |--------------------------|-------|--------------------------------|-------|----------------|-------| | | | | | | | | Contents | | Speakers | | | | | 01 Introduction | | Panna Sharma CEO and President | CFO | David Margrave | | | 02 Q3 2023 Highlights | | | | | | | 03 Financial Highlights | | | | | | | 04 Q&A | | | | | | (*Parker et al., 2021) RADR® can predict and stratify real-world patients for cl ...

Financial Performance - The company reported net losses of approximately $11,776,000 for the nine months ended September 30, 2023, compared to $10,879,000 for the same period in 2022, indicating an increase in losses year-over-year [88]. - Net losses were approximately $11,776,000 for the nine months ended September 30, 2023, compared to $10,879,000 for the same period in 2022 [105]. - Net cash used in operating activities was approximately $10,961,000 for the nine months ended September 30, 2023, compared to approximately $10,099,000 for the same period in 2022 [110]. - The company experienced foreign currency losses of approximately $130,000 for the nine months ended September 30, 2023, compared to $159,000 for the same period in 2022 [120]. - Cash and cash equivalents decreased from approximately $37,202,000 as of December 31, 2022, to approximately $25,572,000 as of September 30, 2023 [108]. Research and Development - Research and development expenses increased by approximately $1,508,000, or 215%, from $702,000 for the three months ended September 30, 2022, to $2,210,000 for the same period in 2023 [99]. - Research and development expenses increased approximately $1,970,000, or 31%, from approximately $6,351,000 for the nine months ended September 30, 2022, to approximately $8,321,000 for the nine months ended September 30, 2023 [103]. - The company is advancing three lead drug candidates and an Antibody Drug Conjugate (ADC) program, all leveraging precision oncology and AI-driven approaches [83]. - LP-300 is currently undergoing a targeted phase II trial for non-small cell lung cancer (NSCLC) in never smoking patients, while LP-100 has shown a median overall survival of approximately 12.5 months in a previous trial [85]. - The ADC program is in preclinical research optimization, with a focus on identifying targeted antibodies for selected compounds [83]. Operating Expenses - The total operating expenses for the nine months ended September 30, 2023, were $13,000,186, compared to $10,606,475 for the same period in 2022 [97]. - General and administrative expenses decreased by approximately $129,000, or 9%, from $1,443,000 for the three months ended September 30, 2022, to $1,314,000 for the same period in 2023 [98]. - General and administrative expenses increased approximately $424,000, or 10%, from approximately $4,255,000 for the nine months ended September 30, 2022, to approximately $4,679,000 for the nine months ended September 30, 2023 [102]. - The company expects to incur significant expenses as it continues to develop its pipeline and build the necessary infrastructure for commercialization [90]. - The company expects to incur significant and increasing operating losses as it continues clinical trials for its drug candidates [113]. Revenue Generation - The company has not generated any revenue to date, relying primarily on equity securities sales to finance operations [88]. Funding and Financial Strategy - The company plans to apply for grant funding in the future to support its capital needs [107]. - The company had no long-term debt outstanding as of September 30, 2023 [118]. Interest Income - Interest income increased approximately $368,000, or 283%, from approximately $130,000 for the nine months ended September 30, 2022, to approximately $498,000 for the nine months ended September 30, 2023 [104].

Financial Data and Key Metrics Changes - The company recorded a net loss of approximately $4.7 million for Q2 2023, or $0.44 per share, compared to a net loss of approximately $4.5 million, or $0.41 per share, for Q2 2022 [60] - R&D expenses increased to approximately $3.6 million in Q2 2023 from approximately $3.0 million in Q2 2022, driven by increases in research studies and payroll expenses [14] - The company maintained a strong cash position with approximately $48 million in cash, cash equivalents, and marketable securities as of June 30, 2023, providing a runway into 2025 [30][61] Business Line Data and Key Metrics Changes - The company has over 14 drug programs, many with orphan drug designations, addressing markets estimated at approximately $14 billion in annual therapy sales [5] - The RADR platform has enabled a 70% reduction in early-stage drug development timelines and an 80% reduction in costs compared to traditional methods [6] - The AI-driven pipeline includes LP-184 and LP-284, which are part of the synthetic lethality franchise showing significant potency in various cancers [37][38] Market Data and Key Metrics Changes - The global market for antibody-drug conjugates (ADCs) is projected to grow from $4 billion to over $14 billion by 2027, indicating significant growth potential in this segment [28][70] - The market for mantle cell lymphoma and double-hit lymphomas is estimated at $1.2 billion in the U.S. and Europe, with a global potential of 2 to 2.5 times that amount [65] Company Strategy and Development Direction - The company aims to leverage AI and machine learning to transform oncology drug discovery, focusing on targeted therapies and reducing costs and timelines [4][46] - A partnership with Bielefeld University in Germany is set to develop next-generation ADCs, enhancing the company's capabilities in this rapidly growing market [27][69] - The company plans to actively explore licensing and partnership opportunities with biopharma companies to accelerate the path to patients for its therapies [47] Management's Comments on Operating Environment and Future Outlook - Management highlighted the need for the industry to rethink its approach to drug pricing and development, emphasizing the role of AI in addressing these challenges [7] - The company is optimistic about the potential of its drug candidates, particularly LP-184, which has an estimated global market potential exceeding $10 billion [63] - The focus for the second half of the year will be on advancing enrollment in clinical trials for LP-184 and LP-300, with expectations for significant progress [46][68] Other Important Information - The company received FDA clearance for its IND application for LP-184 in June 2023, marking a significant milestone for the program [34] - The RADR platform's predictive accuracy is reported at 88% in identifying patients likely to respond to drugs in clinical trials [25] - The company has filed five new patent applications for LP-184 and LP-284, extending commercial protection for these assets [58] Q&A Session Summary Question: Has the first stage of the Harmonic trial enrolled yet? - Yes, the first stage of the trial is in progress, and results will be reported as they are reviewed [79] Question: How will genomic and transcriptomic data from the Harmonic trial guide future trials? - The data from liquid biopsies will help identify specific patient signatures that may respond better to therapies [80] Question: What is the biological difference between genders in the study? - The trial reflects the real-world epidemiology of lung cancer, where a higher proportion of never smokers diagnosed are female [97] Question: Is there preclinical data supporting the combination of pembrolizumab with LP-300? - Currently, there is no specific preclinical data, but the combination may enhance treatment efficacy based on feedback from clinicians [89] Question: How does Lantern Pharma compare to other AI-driven companies in drug discovery? - Lantern's focused approach in oncology and its integration of biology with AI distinguishes it from other companies that may lack direction [92]

Second Quarter 2023 Operating & Financial Results Conference Call / Webinar NASDAQ: LTRN 1 Nasdaq: LTRN RADR® can predict and stratify real-world patients for clinical trials with 88% Accuracy LANTERN'S DRUG DEVELOPMENT MODEL AND OBJECTIVES Accelerated timelines; reduced costs and risks Lantern's diverse & unique AI-driven pipeline of 14 drug programs includes the Phase 2 Harmonic™ trial and RADR® collaborations August 9th, 2023 4:30 PM Eastern Time Forward Looking Statements > Lantern P h a r m a Lantern i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Emplo ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma. Welcome to our First Quarter 2023 Earnings Call. I will be your host for today's call. As a ...

NASDAQ: LTRN LP-300 has additional MoA's that can give it chemo-protective and chemo-sensitization properties • Reduce glutathione/thioredoxin mediated tumor resistance to therapy • Nephrotoxicity protection against chemotherapy LP-300 binding to ALK inactivates it in a dose dependent manner LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy DDR Deficient Tumors Including: Phase 1 trial in 2023* *Anticipated Timeline • Low nanomolar anti-cancer potency, heal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Empl ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Kishor Bhatia - Chief Scientific Officer Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton Nicole Leber Welcome to our fourth quarter and full-year 2022 earnings call. I will be your host for today's ...

March 20th, 2023 4:30 PM Eastern Time Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are ...